Ting Xiao

Partner
CO-HEAD OF LIFE SCIENCES, CHINA

ting.xiao@dlapiper.com

Shanghai
T: +86 21 3852 2111
F: +86 21 3852 2000

Ting is a Partner in the IPT practice of DLA Piper's Shanghai office. She also co-leads the firm’s Life Sciences practice in China. Her practice focuses on patents, trade secrets and other technology-related matters. She specializes in licensing and technology transfer, life sciences and healthcare related regulatory work, and also handles IP enforcement and litigation matters.

Prior to her legal career, Ting worked as a research scientist in the National Key Laboratory of Chinese Academy of Sciences and a renowned research institute in Canada. Ting leverages her advanced scientific research background and deep understanding of client’s technical field to routinely advise clients from a wide variety of emerging and innovative sectors, including life sciences and healthcare, chemical, automotive, information technology, artificial intelligence and new energy.

- Intellectual Property and Technology

- Technology
- Life Sciences

Chinese (Mandarin)
English

LANGUAGES SPOKEN

- Chinese (Mandarin)
- English

- Representing one of the largest Chinese pharmaceutical CDMOs/CROs in multiple cross-border transactions, including an in-license of DNA library screening technology from a top U.S. university, a joint development and collaboration agreement with a U.S. supplier of API compounds, and multiple outbound service agreements.
- Representing an Irish company in a distribution arrangement with one of the largest pharmaceutical conglomerate in China relating to a novel drug.
- Advising a large Vietnamese conglomerate on a complex technology and IP in-licensing, component supply and services transaction with a Chinese state-owned automobile manufacturer involving the Chinese automobile OEM’s electrical and electronic (E/E) architecture.

- Acting for a major U.S. lithium battery company in negotiating and drafting a joint development and manufacturing agreement with a Central State Owned Enterprise for the manufacture of ultrahigh capacitor batteries in China for use in the public transport road and rail infrastructure.
- Advising a major Chinese OEM of electronic devices in a legal action brought by its licensor in U.S. concerning disputes on royalty payment and trademark infringement.
- Advising a U.S. application-delivery-networking-technology company on complex transaction with Chinese partner to have networking equipment “made in China” and distributed in China, including preparing manufacturing and IP license agreement as well as component supply agreement.
- Advising a German banking IT system provider on complex licensing, back licensing and technology transfer issues in connection with its joint venture arrangement with a Chinese state-owned enterprise.
- Advising a major American manufacturer of diagnostic healthcare products on various NMPA regulatory and compliance issues concerning its China entry.
- Advising biotechnology companies, third party laboratories, CROs, pharmaceutical companies and other life sciences companies in connection with genetic resources regulations and Biosecurity Law compliance issues.

CREDENTIALS

Professional Qualifications

- Attorney-at-law admitted with the Supreme Court of New York
- Barrister and Solicitor registered with The Law Society of Upper Canada
-

Recognitions

- Ting has been consistently enlisted as "IP Star-Rising Star" by *Managing Intellectual Property* for year 2018/2019, year 2019/2020 and year 2020/2021.
- Ting has been consecutively recognized by *Legal 500* as "Rising Star" for China’s Healthcare and Life Sciences practice in year 2019/2020 and year 2020/2021.

Education

- University of Toronto, Juris Doctor
- University of Toronto, Master of Science
- Wuhan University, Bachelor of Science (Ranked 2nd out of 210)

INSIGHTS

Publications

New medical device regulations in China likely to lead to increased regulatory enforcement

3 May 2021
The Chinese State Council has passed the eagerly anticipated revisions to the PRC's Regulations for Supervision and Administration of Medical Devices, which will come into effect on 1 June 2021. The Regulations will significantly increase the range and size of penalties that may be imposed for regulatory violations.

China's Revised Regulations on Medical Devices: Good News for Industry Stakeholders?

21 April 2021
On 9 February 2021, the PRC State Council issued the revised PRC Regulations on the Supervision and Administration of Medical Devices (the Revised Medical Device Regulations), which will become effective on 1 June 2021.

China signs off on PRC Biosecurity Law: What this means for industry players in China

21 October 2020
The Biosecurity Law establishes a comprehensive framework replacing the current somewhat piecemeal legislation.

Back to business guide - China

18 May 2020
The first edition of our China back to business guide was issued on April 10, two days after China lifted its nearly three-month lock-down of Wuhan, the last city in China to do so. A month later, businesses are resuming operations, schools are reopening, and life is returning to normal, albeit with caution.

2018 Outlook for Drugs and Medical Devices in China: Regulatory Reform Fueled by Innovation

NEWS

DLA Piper announces partnership promotions for 2022

28 April 2022
DLA Piper is proud to announce that 74 lawyers have been promoted to its partnership. The promotions are effective as of April 1 2022 in the United States and May 1 2022 for EMEA and Asia Pacific. Promotions have been made across all of the firm's practice areas, spanning 38 offices in 21 countries.